Login / Signup

Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach.

Toby M MaherKevin K BrownSteven CunninghamEmily M DeBoerRobin DeterdingElizabeth K FiorinoMatthias GrieseNicolaus SchwerkDavid WarburtonLisa R YoungMartina GahlemannFlorian VossChristian Stocknull null
Published in: Pediatric pulmonology (2024)
These findings, together with the safety data from the InPedILD trial, support the use of nintedanib in children and adolescents with fibrosing ILDs.
Keyphrases
  • interstitial lung disease
  • idiopathic pulmonary fibrosis
  • systemic sclerosis
  • rheumatoid arthritis
  • electronic health record
  • phase iii
  • study protocol
  • clinical trial
  • phase ii
  • big data
  • data analysis
  • machine learning